# Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine

> **NCT00304265** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 215 (actual)

## Conditions studied

- Pertussis
- Diphtheria
- Tetanus
- Poliomyelitis

## Interventions

- **BIOLOGICAL:** COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)

## Key facts

- **NCT ID:** NCT00304265
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2006-10
- **Final completion:** 2007-10
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2016-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00304265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00304265, "Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00304265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*